A Phase 4, Open-Label Study of a Single Dose of Vyleesi? (Bremelanotide Injection) in Healthy, Premenopausal Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk

The primary objectives of this clinical trial performed with Vyleesi (Bremelanotide Injection) are:
* to evaluate if Bremelanotide (BMT) is secreted in breast milk of lactating women treated with a single dose of BMT 1.75 mg SC.
* to measure the concentration and characterize the pharmacokinetics of BMT secreted in breast milk of lactating women treated with a single dose of BMT 1.75 mg SC.
This open-label, pharmacokinetic (PK) study will be performed in 10 healthy lactating female subjects between 10 days and 6 months post-partum (inclusive). The maximum duration of subject participation in the study will be approximately 29 days, consisting of 3-week Screening period, a 1 day treatment period, and up to a 7 day follow-up period.

开始日期2025-06-26

申办/合作机构

Cosette Pharmaceuticals, Inc.

NCT06565611

/ Active, not recruiting临床2期

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide With Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).

开始日期2024-08-05

申办/合作机构

Palatin Technologies, Inc.

NCT05709444

/ Completed临床2期

A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease to Assess the Efficacy in Reducing Urinary Protein and Maintaining Podocyte Density and Function

This is a prospective, open-label trial to assess the efficacy of melanocortin receptor agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy. After six months of therapy, all subjects will remain in trial for further assessment and undergo a diagnostic renal biopsy to assess the effect of melanocortin therapy on diabetic histopathology at 12 months.

开始日期2022-12-26

申办/合作机构

Palatin Technologies, Inc.

100 项与布美诺肽相关的临床结果

登录后查看更多信息

100 项与布美诺肽相关的转化医学

登录后查看更多信息

100 项与布美诺肽相关的专利（医药）

登录后查看更多信息

104

项与布美诺肽相关的文献（医药）

2025-08-01·JOURNAL OF CONTROLLED RELEASE

A biodegradable suction patch for sustainable transbuccal peptide delivery

Article

作者: Rabut, Lucie ; Klein Cerrejon, David ; Dehapiot, Benoit ; Gao, Daniel ; Zoratto, Nicole ; Leroux, Jean-Christophe ; Paunović, Nevena ; Krupke, Hanna

Despite considerable advances in the systemic delivery of peptides, their susceptibility to gastrointestinal degradation and high molecular weight, which restricts permeability across biological barriers, remain obstacles to oral administration. As a result, most peptide therapies rely on injections to achieve therapeutic effects. Recent studies on a bioinspired suction patch demonstrated positive effects in vivo with three peptides - desmopressin, semaglutide, and teriparatide - yet materials used for patch fabrication were non-degradable. In this work, a more sustainable patch alternative is introduced by replacing previously used materials with biodegradable polymers, aiming for degradation of the patch after removal to reduce environmental impact. A scalable mold casting process was employed to thermally crosslink synthesized and functionalized copolyesters, yielding the desired devices. Mechanical testing across various materials and shapes identified the best-performing polymer, while its degradation was confirmed in both aqueous medium and simulated waste. An ex vivo model using porcine buccal tissue validated the functionality of biodegradable patches, showing enhanced permeation of a poorly permeable dye when combined with a chemical permeation enhancer. In beagle dogs, the bioavailability of semaglutide (4.11 kDa) was substantially improved compared to the commercially available tablet, with an application time of only 10 min. Additionally, the patch achieved a relative bioavailability of 26% for bremelanotide (1.03 kDa) compared to subcutaneous administration. This work underscores the potential of replacing silicone devices with biodegradable alternatives, providing a more sustainable approach for peptide delivery via the buccal suction patch.

2025-07-01·SUPPORTIVE CARE IN CANCER

2024 SOGC, 2024 NCCN, 2022 ESO-ESMO, and 2018 ASCO: a comparison of female cancer survivorship guidelines for the management of sexual health concerns

Review

作者: Faouk Al Aadah, Carmen ; Al-Khaifi, Muna ; Bhinder, Jashmira K ; Kennedy, Samantha K F

PURPOSE:

Female cancer survivors often experience sexual dysfunction, which is a significant and increasingly recognized aspect of survivorship. This review compares guidelines from the American Society of Clinical Oncology (ASCO), the European School of Oncology-European Society of Medical Oncology (ESO-ESMO), the National Comprehensive Cancer Network (NCCN), and the Society of Obstetricians and Gynaecologists of Canada (SOGC) for managing sexual health symptoms.

METHODS:

The most recent guidelines from ASCO, ESO-ESMO, NCCN, and SOGC were examined and compared. The recommendations were grouped by type of sexual dysfunction: vaginal dryness, low sex drive, pain, orgasmic dysfunction, and psychological concerns.

RESULTS:

All guidelines strongly recommend non-hormonal therapies (i.e., lubricants or moisturizers) as first-line treatments for managing vaginal dryness. If unsuccessful, there is consensus for low-dose estrogen creams, tablets, capsules, or rings as second-line treatments. Multidisciplinary care is also recommended by all, including psychosocial and relationship counselling, specialist referrals, and cognitive behavioral therapy to address psychological concerns. ASCO, NCCN, and SOGC recommend vaginal dilators, and pelvic physical therapy for relieving pain. ASCO recommends any kind of stimulation (including masturbation) to improve sexual response, while NCCN and SOGC recommend the use of sexual aids (e.g., vibrators) to enhance arousal. Although all guidelines, except ESO-ESMO, include recommendations for androgens, bupropion, flibanserin, bremelanotide, and buspirone for low sex drive, there is limited data.

CONCLUSION:

There is consensus among guidelines on certain sexual health recommendations, with some variation. Additional research is needed on pharmacological interventions and types of counselling to strengthen their evidence.

2025-06-01·Journal of Minimally Invasive Gynecology

Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options

Article

作者: Hacker, Michele R ; Winkelman, William D ; Reyes-Gonzalez, Daniela ; Toledo, Rafaela Germano ; Fladger, Anne ; Bergeron, Sophie ; Anand, Mallika

OBJECTIVE:

To conduct a systematic review and meta-analysis of treatments for female sexual desire, arousal, and orgasmic dysfunction in patients without sexual pain conditions.

DATA SOURCE:

MEDLINE, Embase, Web of Science, Cochrane Library, PsycINFO, and ClinicalTrials.gov.

METHODS OF STUDY SELECTION:

Following the initial search in December 2024, a total of 8994 abstracts were screened, 278 full-text articles were reviewed, and 36 studies met criteria for data abstraction including a patient population with female sexual dysfunction (FSD) of desire, arousal, and/or orgasm (DAO) and outcome measures including the Female Sexual Function Index (FSFI), its DAO subscales, and the Female Sexual Distress Scale (FSDS). Studies including patients with sexual pain conditions were excluded. Two reviewers independently conducted each phase.

TABULATION, INTEGRATION, AND RESULTS:

Of the 36 studies, 26 were RCTs and 10 were single-arm trials. Ten studies evaluated cognitive behavioral therapy (CBT), 24 investigated medication therapy, and 2 investigated devices. Meta-analyses were conducted for mindfulness-based CBT, flibanserin, and bremelanotide. Mindfulness-based CBT significantly improved total FSFI and subscales of desire, arousal, and orgasm. Conversely, flibanserin improved total FSFI and desire while bremelanotide improved total FSFI and its desire and arousal subscales. No studies directly compared CBT to pharmacotherapy.

CONCLUSION:

In this systematic review of treatments of females with sexual DAO dysfunctions without pain, we found that CBT improves DAO; flibanserin improves desire; and bremelanotide improves both desire and arousal; and all 3 treatments reduce distress. Our findings align with previous literature and expand upon it to include multiple treatment modalities. This broader perspective offers a starting point for clinicians, including gynecologists, who frequently serve as the first point of care for FSD. Conclusions regarding most other treatments could not be drawn due to limited numbers of studies of FSD excluding pain, heterogeneous terminology for DAO disorders, and varying outcome measures across studies.

项与布美诺肽相关的新闻（医药）

2025-08-18

·FierceBiotech

Boehringer pens $327M pact with Palatin to develop new therapies for diabetic retinopathy

The research and licensing deal centers around diabetic retinopathy, a leading cause of blindness for adults.\n Boehringer Ingelheim has inked a deal with Palatin Technologies worth up to €280 million (about $327 million) biobucks with the aim of developing new retinal disease therapies. The German drugmaker will work with the New Jersey-based biopharma to create potentially first-in-class therapeutics based on molecules that regulate the melanocortin receptor system. The system is involved in several bodily functions, including inflammation, immune response, metabolism, steroid hormone production and sexual function.In particular, the research and licensing deal centers around diabetic retinopathy (DR), a complication of diabetes that is a leading cause of blindness for adults.Palatin has a research program in DR, and more specifically, in diabetic macular edema (DME), a complication of DR that impacts the retina. The biopharma’s pipeline focuses on melanocortin receptor agonists in hopes of developing a differentiated mechanism that targets key drivers of certain diseases.Boehringer is offering up to $327 million in upfront, development, regulatory and commercial milestone payments, plus tiered royalties, according to an Aug. 18 release.“Millions of people worldwide face a progressive decline in their independence and connection to the world due to vision loss caused by complications of diabetic retinopathy, such as DME,” Remko Bakker, Boehringer’s head of eye health and research beyond borders, said in the release. “Given the high treatment burden associated with DR, the potential of a melanocortin receptor agonist is a strategic fit with our pipeline focusing on addressing the three main drivers of retinal disease: inflammation, vascular dysfunction, and neurodegeneration.”“Importantly, this mechanistic approach may also be applicable in retinal diseases beyond DR where high unmet needs remain,” Bakker added. The German drugmaker has recently upped its efforts in eye health, with four clinical programs in its publicly disclosed pipeline designed to prevent or restore vision loss for impacted patients. Besides DR, the company is particularly focused on wet age-related macular degeneration and geographic atrophy.Just a few weeks ago, the pharma penned a $1 billion biobucks pact with Re-Vana Therapeutics that centers around the biotech’s ocular drug delivery tech, which is designed to reduce the need for ophthalmic patients to receive regular injections by slowly releasing treatments into the eye.As for Palatin, the company has one approved product on the market for hypoactive sexual desire disorder. The injection, sold as Vyleesi (bremelanotide), is made to activate melanocortin receptors in the brain to boost sexual desire in premenopausal women.On the development side, the biopharma’s most advanced clinical program—a dry eye disease drug called PL9643—failed to meet the main goal of a phase 3 study last year. Despite the miss, the company is forging ahead with a new late-stage program for the asset that\'s slated to start in the first half of next year, according to a corporate presentation (PDF) published in August. The biopharma is “seeking development and commercial partnerships” for PL9643, according to the presentation.Since the new pact with Boehringer was announced this morning, Palatin’s stock price has jumped 24% to $6.88 as of 10:30 a.m. ET.

临床3期引进/卖出

2025-07-07

·CPHI制药在线

环肽的药理作用研究进展（二）

关注并星标CPHI制药在线在环肽中，除了上文简述的抗癌、抗细菌和抗真菌活性，环肽还具有抗炎、抗病毒以及其他药物活性。相关阅读：《环肽的药理作用研究进展（一）》04抗炎环肽研究表明，环肽因其独特的生物活性和稳定性，正成为治疗炎症性疾病的有力候选者。Flaxseed linusorbs（FLs）是从亚麻籽油中提取的环肽，已显示出抗炎作用。在脂多糖（LPS）诱导的 RAW 264.7 细胞中，FLs 可通过靶向抑制 TLR4 的激活来抑制 NF-κB/MAPK 信号通路的调节，可显著抑制炎症细胞因子（即TNF-α、 IL-1β和 IL-6）和炎症介质蛋白（即 iNOS 和Cox-2）的转录和表达。大环化合物 X15856是一种新型六环肽的类肽混合物，其在 LPS 刺激的 BV2 小胶质细胞中具有抗炎作用，在LPS 处理的 BV2 小胶质细胞中能显著抑制IL-6、TNF-α、c-c 基序趋化因子配体2（CCL2）、CCL3、C-X-C 基序趋化因子配体 2（CXCL2）和 CXCL10 的表达和释放。该化合物的抗炎作用部分可以通过调节 p38 丝裂原活化蛋白激酶（MAPK）、 p42/44 MAPK（ERK1/2）、蛋白激酶 C（PKC）和核因子（NF）-κB 的磷酸化来解释。05抗病毒环肽目前已经上市的抗病毒类环肽药物有帕利瑞韦（paritaprevir）、格拉瑞韦（grazoprevir）、伏西瑞韦（voxilaprevir）。这三种药物都主要用于治疗慢性丙型肝炎病毒（HCV）感染，特别是针对基因型 1的 HCV 感染。三者都是通过抑制 HCV 的蛋白酶（特别是 NS3/4A 蛋白酶）来发挥抗病毒作用。NS3/4A蛋白酶在 HCV 的多蛋白加工和病毒复制过程中起关键作用，因此抑制该酶可以阻断病毒的复制。环肽药物与其他抗病毒药物相比具有明显的优势，已成为目前新药研发的一种新趋势。Aspergillipeptide D是从真菌曲霉属（Aspergillus sp.）的培养液中分离出来的一种环状五肽，其对Vero 细胞系（IC50= 9.5 μmol/L）的非细胞毒性浓度下，对 1型单纯疱疹病毒（HSV-1）表现出良好的抗病毒活性。它还显示出对 HSV-1-106 和HSV-1-153（对阿昔洛韦有抗药性的临床分离株）具有近 50%的抗病毒活性。在深海衍生的真菌菌株Simplicillium中分离的环肽 Simplicilliumtides J 对Aspergillus versicolor和Curvularia australiensis表现出显著的抗真菌活性和抗 HSV-1 作用，IC50值分别为14.0、16.7 和15.6 μmol/L。Simplicilliumtides K 是从深海来源的菌株Simplicillium obclavatum EIODSF 020.87 中发现的，它对 HSV-1 表现出有效的抗病毒活性，IC50值为14.0 μmol/L。还有研究报道了流感病毒包膜蛋白血凝素相结合的一类环肽- iHA的开发。在所研究的 28 种iHA 中，iHA-24 和iHA-100 对体外多种甲型流感病毒复制具有抑制作用。特别是 iHA-100，它能通过结合血凝素的活性区域，对血凝素介导的吸附和膜融合过程展现出双重抑制作用。在小鼠和食蟹猕猴的实验模型中，iHA-100 环肽展现出了显著的抑制高致病性流感病毒增殖的能力，并能有效预防感染后期可能导致的严重肺炎。还有研究报道根据雉鸡抗菌素（pheasant cathelicidin）的结构特征，设计并合成了一系列肽类物质。研究结果表明，在这些设计的肽类物质中，Pc-4 与Pc-5 展现出了对 H1N1 病毒复制的显著抑制效果。 Pc-5 能够强力诱导 I型干扰素生成及干扰素诱导基因的表达，这一新发现凸显了 Pc-5 作为治疗 H1N1 病毒感染的新型候选药物的巨大潜力和价值。06其他生物活性环肽近年来，许多具有其他生物活性的环肽也被报道。例如，伏环孢素（voclosporin）是环孢素的一种衍生物，当前被视为一种极具潜力的钙调神经磷酸酶抑制剂。它通过抑制钙调神经磷酸酶的活性，进而阻断白细胞介素-2 的表达，抑制 T细胞介导的免疫反应，从而稳定肾脏足细胞。相较于传统的钙调神经磷酸酶抑制剂，伏环孢素展现出了更为可预测的药代动力学与药效学特性（可能无须进行治疗药物监测），具有更强的效力（相较于环孢素 A）以及更优的代谢特征。肢端肥大症是一种罕见且诊断困难的疾病，95%以上的病例是由生长激素（GH）分泌的垂体腺瘤引起。生长抑素受体配体（SRL）是目前治疗肢端肥大症的一线用药，可以使 40%～70%患者GH和IGF -1 水平正常，并能改善肢端肥大症患者高血糖、高血压、心功能不全等并发症。第一代 SRL 包括奥曲肽（octreotide）、奥曲肽长效缓释剂和兰瑞肽（lanreotide），第二代 SRL 为帕瑞肽（pasireotide）。生长抑素（somatostatin）是一种含二硫键的 14 肽环肽，对受体活性强且亲和力高，但血浆半衰期极短（<3 min）。通过骨架环化（如二硫键、酰胺键）优化，得到的一代类似物奥曲肽和兰瑞肽（八肽），均缩小了骨架环大小并保留了关键药效团。奥曲肽于 1988 年上市，用于治疗肢端肥大症，半衰期提升至约 100 min，较生长抑素提高 33 倍。兰瑞肽于 1990 年在欧洲上市，2007 年获 FDA 批准，同样用于治疗肢端肥大症，活性更强且作用持久，给药频率低至每 2周或每月一次。二代类似物帕瑞肽进一步缩小骨架环，保留关键药效团并引入脯氨酸头尾酰胺键关环，增强分子刚性。该药物于 2012 年获 EMA 和FDA 批准用于治疗库欣病，2014 年再获 FDA 批准用于肢端肥大症治疗，帕瑞肽与靶点的结合亲和力超越一代类似物。α-促黑色素激素（afamelanotide）是一种由前黑素皮质素蛋白水解产生的线性 13 肽衍生物，对皮肤色素沉着调节具有关键作用。然而，由于其易受蛋白酶水解影响，体内半衰期较短。通过构效关系研究，确定了调节皮肤色素沉着及其他促黑色素激素功能的关键药效（His-Phe-Arg-Trp）。基于这一发现，通过赖氨酸与天门冬氨酸侧链的内酰胺桥合成了布美兰肽（bremelanotide），以及利用半胱氨酸侧链间的二硫键桥合成了司美诺肽（setmelanotide）。其中，布美兰肽作为一种非选择性黑皮质激素受体激动剂，主要作用于 GPCRs 家族的 MC3 和MC4 受体，于 2019 年获得 FDA 批准，用于治疗绝经前女性的全身性性欲减退症，其半衰期达到 2.7 h。司美诺肽于 2020 年被 FDA 批准用于治疗罕见遗传性肥胖症，可优先激动 GPCR 受体-MC4R，可有效减轻由 POMC、PCSK1 或LEPR 缺乏导致的个体肥胖，这三种蛋白的基因变异会损伤 MC4R 通路（负责调节饥饿和能量消耗）。Pentaminomycin A和B 是从链霉菌属菌种的培养物中获得了两个环状肽。Pentaminomycin A 通过减缓酪氨酸酶、酪氨酸酶相关蛋白-1（TRP-1）和酪氨酸酶相关蛋白 2（TRP-2）等黑色素生成酶的表达来抑制α-MSH 刺激的黑色素的合成。Anabaenopeptins 1是从波罗的海蓝藻提取物中提取的具有生物活性的环状六肽，该物质包含Dolichospermum spp.（10%）、Aphanizomenon flos-aquae（40%）和Nodularia spumigena（50%）。它们均对蛋白质磷酸酶 1和羧肽酶 A表现出抑制作用，但对胰蛋白酶、胰凝乳蛋白酶和凝血酶没有抑制作用。Peginesatide是FDA 近年来批准上市的第一个从头开发的药物，该药用于治疗无法使用促红细胞生成素所导致的严重贫血。另有研究中通过针对红细胞生成素的噬菌体逐级筛选而发现的受体。然后将其与聚乙二醇（PEG）发生二聚，从而增加血液中的亲和力、效力和循环时间，但是遇到临床试验中的许多问题，在批准一年后自愿退出市场。除这些化合物外，最近还报道了许多其他生物活性环肽。例如，环亚麻肽（CL）除了具有抗疟和免疫抑制作用之外，还具有破骨细胞分化抑制活性。该小组利用 TRAP 活性作为破骨细胞分化的指标，筛选了在先前的植物化学研究中分离出的化合物，结果发现，环亚麻肽所显示出的破骨细胞分化抑制活性能力明显强于阳性对照。新型环肽蛋白模拟物 c(MyD 4-4)可抑制TLR 配体的炎性反应以及对 NF-κB 进行激活。该种环肽可以特异性地阻断髓样分化因子（MyD88），防止 MyD88 二聚化，以及降低小鼠多发性硬化症。参考资料[1]陈恩奇,马惠钟,王昱壁,等.环肽在药学领域的应用进展[J].药学学报,2025,60(05):1390-1406.[2]董家潇,宋亚红,李修政,等.环肽的结构多样性及药理作用[J].河北医药,2022,44(19):3009-3013+3019. 作者简介：小泥沙，食品科技工作者，食品科学硕士，现就职于国内某大型药物研发公司，从事营养食品的开发与研究。END智药研习社近期直播预告来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

临床研究

2025-06-16

·PRNewswire

Peptide and Anti-Aging Specialist Dr. Daniel Benhuri Now Offering Advanced Peptide Therapy, Including Semaglutide, in Beverly Hills and Los Angeles

Dr. Daniel Benhuri, a board-certified concierge physician in Beverly Hills, has introduced personalized peptide therapy to help patients optimize energy, metabolism, immunity, and recovery. The new service is available in-office or via concierge care throughout Beverly Hills and Los Angeles. BEVERLY HILLS, Calif. , June 16, 2025 /PRNewswire/ -- Dr. Daniel Benhuri, a board-certified internal medicine physician and highly rated concierge doctor in Beverly Hills, is now offering a full range of advanced peptide therapies designed to support weight loss, healing, hormone balance, sexual wellness, and cellular rejuvenation. Serving patients throughout Beverly Hills and the greater Los Angeles area, Dr. Benhuri's peptide programs now include widely requested options like Semaglutide, Tirzepatide, Tesamorelin, PT-141, BPC-157, and NAD+. Continue Reading Daniel Benhuri MD Peptides are short chains of amino acids that function as biological messengers, helping regulate metabolism, inflammation, recovery, and tissue repair. Dr. Benhuri's therapy protocols are fully customized based on labs, medical history, and patient goals—and are now available through in-office visits or concierge care across Los Angeles. "Peptide therapy is a powerful tool that allows us to treat the root causes of fatigue, weight gain, inflammation, and low libido," said Dr. Benhuri. "These are evidence-based, well-tolerated therapies that fit perfectly into our concierge wellness model. Our patients want to optimize their lives, and peptides help us deliver exactly that." Highlights of Dr. Benhuri's peptide therapy offerings include: Semaglutide and Tirzepatide (GLP-1 agonists): Support sustainable weight loss by regulating appetite and improving insulin sensitivity. Tesamorelin: Helps reduce visceral fat and promote lean muscle development. PT-141: Enhances sexual desire and performance in both men and women. BPC-157: Accelerates healing of soft tissue injuries and provides anti-inflammatory benefits. NAD+ Therapy: Though not a peptide, NAD+ is a key coenzyme used for energy metabolism, anti-aging, and cognitive enhancement. Dr. Benhuri's comprehensive programs begin with a detailed consultation and lab review. Based on individual needs, patients receive a personalized treatment plan that may include injectable peptides, nasal sprays, or topical solutions—all sourced from high-quality U.S. compounding pharmacies. Patients also benefit from ongoing clinical monitoring and adjustments as part of his concierge approach. Known for his expertise in preventive care, weight management, and regenerative medicine, Dr. Benhuri offers these new services as a natural extension of his commitment to helping patients feel better, function better, and age with confidence. More About Dr. Daniel Benhuri Dr. Daniel Benhuri is a highly respected internal medicine and primary care physician serving patients in Beverly Hills and the surrounding areas. He offers a vast array of services, including advanced diagnostic imaging, executive physicals, medical weight loss plans, preventive care, and aesthetic treatments. By integrating concierge care and cutting-edge technology, Dr. Benhuri delivers an unmatched level of patient-focused care. His practice is located at 9400 Brighton Way, Suite 210, Beverly Hills, CA 90210. For more information or to schedule an appointment, visit or call (310) 362-1255. Media Contact Dr. Daniel Benhuri (310) 362-1255 SOURCE Daniel Benhuri M.D. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与布美诺肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	布美诺肽	G	DB11653

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心理性性功能障碍	美国	Cosette Pharmaceuticals, Inc.	2019-06-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
女性性功能障碍	临床3期	加拿大	Palatin Technologies, Inc.	2014-12-31
肥胖	临床2期	美国	Palatin Technologies, Inc.	2024-08-05
糖尿病肾病	临床2期	美国	Palatin Technologies, Inc.	2022-12-26
勃起功能障碍	临床2期	美国	Palatin Technologies, Inc.	-
性欲障碍 NOS	临床1期	中国	Palatin Technologies, Inc.	2020-10-16
性欲障碍 NOS	临床1期	中国	上海复星医药产业发展有限公司	2020-10-16
出血性休克	临床前	美国	Palatin Technologies, Inc.	-
血管疾病	临床前	美国	Palatin Technologies, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06565611 (BMT-801, PRNewswire) 人工标引	临床2期	肥胖	-	bremelanotide + tirzepatide	鏇願網顧襯鬱簾齋衊選(顧齋積艱襯願糧鑰願鹽) = 鬱餘鹹鑰壓醖窪鏇觸鬱衊網繭淵窪糧簾淵構膚 (鬱壓壓觸鏇齋繭壓簾積 ) 更多	积极	2025-04-17
NCT06565611 (BMT-801, PRNewswire) 人工标引	临床2期	肥胖	-	Bremelanotide alone	鏇願網顧襯鬱簾齋衊選(顧齋積艱襯願糧鑰願鹽) = 選簾簾鑰淵鏇構築願築衊網繭淵窪糧簾淵構膚 (鬱壓壓觸鏇齋繭壓簾積 ) 更多	积极	2025-04-17
NCT06565611 (BMT-801, Company_Website) 人工标引	临床2期	肥胖	113	Bremelanotide + Tirzepatide	簾蓋獵廠齋範夢製鹽廠(築窪窪獵夢鹽築顧齋餘) = 窪鏇壓鏇選構艱夢襯簾願壓觸觸遞築襯簾簾觸 (構鏇選願繭窪築積夢選 ) 达到更多	积极	2025-03-31
NCT06565611 (BMT-801, Company_Website) 人工标引	临床2期	肥胖	113	tirzepatide	簾蓋獵廠齋範夢製鹽廠(膚願鹹衊壓襯壓廠糧膚) = 鬱齋鹽鏇鹽鹽淵獵觸壓襯醖範顧襯壓衊願鹹鹽 (製夢壓衊網糧蓋觸鑰範 ) 更多	积极	2025-03-31
NCT05709444 (BREAKOUT Study (BMT-701), NEWS) 人工标引	临床2期	2型糖尿病肾脏病	8	Bremelanotide	願觸鏇繭製築築獵鹹築(鬱艱齋襯醖築艱醖鬱淵) = 獵簾網齋窪襯鹽壓獵夢製鬱鬱衊製齋夢構糧廠 (顧壓襯窪範鏇夢憲醖齋 ) 更多	积极	2024-12-19
NCT04179734 (RF01 \| PMON43, CTgov)	临床4期	心理性性功能障碍 \| 性欲减退	40	Placebo+Bremelanotide	廠鏇齋築淵鬱鬱願鏇鬱 = 製鬱廠觸遞鑰鑰積膚壓簾蓋壓網選夢窪鹹壓築 (選築鹹廠願糧鹽窪網積, 憲衊醖築鏇繭範廠範鬱 ~ 鹹願餘壓範衊顧憲獵鏇) 更多	-	2024-08-09
AUA2024	N/A	性功能障碍	444	Bremelanotide	網鏇糧鏇範構鹽積蓋齋(鏇窪願襯鑰積繭範糧淵) = 範選夢餘構範艱糧衊蓋艱網膚顧範鬱鹽淵鏇鹽 (鏇構壓艱獵鑰選顧齋網 ) 更多	积极	2024-05-01
NCT01382719 (CTgov)	临床2期	心理性性功能障碍	612	bremelanotide (Placebo)	艱繭願觸製艱憲鏇網膚(網憲淵簾網構顧鑰選網) = 繭鏇醖窪壓繭願壓淵範鏇願蓋鏇襯繭淵構積獵 (築遞簾製鹹廠壓築齋觸, 2.29) 更多	-	2014-04-14
NCT01382719 (CTgov)	临床2期	心理性性功能障碍	612	bremelanotide (Bremelanotide Arm 1)	艱繭願觸製艱憲鏇網膚(網憲淵簾網構顧鑰選網) = 選糧鏇鹽齋獵憲廠醖鏇鏇願蓋鏇襯繭淵構積獵 (築遞簾製鹹廠壓築齋觸, 3.55) 更多	-	2014-04-14